|
 |
Article Review/Hyperlink
|
Bennett WG, Inoue Y, Beck R, Wong JB, Pauker SG, Davis GL
Estimates of the cost-effectiveness of a single course of
interferon-alpha2b in patients with histologically mild chronic
hepatitis C
Ann Intern Med
(Nov) 127:855-865 1997

There are three full text papers and one editorial in the November 1997
Annals of Internal
Medicine pertaining to treatment of hepatitis C.
The first paper by
Bennett and the authors listed above, studied the cost
effectiveness
of interferon-alpha2b as a function of age, and found therapy to be cost-
effective in
younger patients, but not in older patients.
The second paper, by
Kim et al, compared cost-effectiveness of 6 and 12 month regimens
of interferon-alpha for hepatitis C, and found both to be cost effective
for patients < 60 years of age, with the 6 month regimen being more cost
effective, but less efficacious.
The third study, by
Marcellin and colleagues, looks at long-term histologic
improvement and
intrahepatic HCV RNA in those patients who do have a sustained response to
interferon alpha
therapy.
All of the data are summarized in an
editorial by RS Koff, who concludes that interferon alpha Rx is
both effective
and affordable. Unfortunately, the exciting dual therapy using interferon
plus
ribavirin, and the attendant higher response rate associated with this new
therapy, are not touched
upon in these papers. (John T. Daugirdas, M.D., University of Illinois
at Chicago)
Related Folders: |
 |
|
|
|
|